The company was previously listed on the Singapore Exchange (SGX:S68
) but was privatised in 2016 by its CEO Richard Eu together with Tower Capital, a unit of Temasek Holdings. At that time, the deal valued Eu Yan Sang at US$196 million.
China's Hillhouse and Japan's Mitsui & Co are reportedly final bidders ready to acquire Eu Yan Sang International for more than US$700 million, reported Reuters.
Singapore-based Eu Yan Sang is a household name in traditional Chinese medicine in southeast Asia and Hong Kong.
